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Abstract
Objective—Asthma severity is defined as the intensity of treatment required to achieve good 
control of asthma symptoms. Studies have shown that work-related asthma (WRA) can be 
associated with poorer asthma control and more severe symptoms than non-WRA. Associations 
between asthma medications and WRA status were assessed using data from the 2012–2013 
Asthma Call-back Survey among ever-employed adults (≥18 years) with current asthma from 29 
states.
Methods—Persons with WRA had been told by a physician that their asthma was work-related. 
Persons with possible WRA had asthma caused or made worse by their current or previous job, but 
did not have physician-diagnosed WRA. Asthma medications were classified as controller (i.e., 
long-acting β-agonist, inhaled corticosteroid, oral corticosteroid, cromolyn/nedocromil, 
leukotriene pathway inhibitor, methylxanthine, anticholinergics) and rescue (i.e., short-acting β-
agonist). Demographic and clinical characteristics were examined. Associations between asthma 
medications and WRA status were assessed using a multivariate logistic regression to calculate 
adjusted prevalence ratios (PRs).
Results—Among an estimated 15 million ever-employed adults with current asthma, 14.7% had 
WRA and an additional 40.4% had possible WRA. Compared with adults with non-WRA, those 
with WRA were more likely to have taken anti-cholinergics (PR=1.80), leukotriene pathway 
inhibitor (PR=1.59), and methylxanthine (PR=4.76), and those with possible WRA were more 
likely to have taken methylxanthine (PR = 2.85).
Conclusions—Results provide additional evidence of a higher proportion of severe asthma 
among adults with WRA compared to non-WRA. To achieve optimal asthma control, adults with 
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WRA may require additional intervention, such as environmental controls or removal from the 
workplace exposure.
Keywords
ACBS; BRFSS; WRA
Introduction
Asthma is a chronic airway disease that affected 18.7 million adults in the United States in 
2010 [1]. Symptoms of asthma include shortness of breath, chest tightness, and wheezing 
caused by airflow obstruction due to reversible narrowing of bronchial airways and an 
increase in bronchial responsiveness to inhaled stimuli [1, 2]. In 2009, asthma was 
responsible for more than 1.3 million emergency department visits, 350 000 hospitalizations, 
and 3500 deaths among adults with current asthma [1]. Work-related asthma (WRA) is the 
asthma that is caused or made worse by workplace exposures, and has been associated with 
poorer asthma control, increased asthma attacks, more emergency department visits, greater 
asthma-related hospitalizations, and more frequent urgent treatment for worsening asthma 
[3, 4].
For most asthma patients, asthma symptoms can be controlled by implementing effective 
asthma treatment and environmental controls [5]. The National Asthma Education and 
Prevention Program’s (NAEPP) Expert Panel Report 3 (EPR-3): Guidelines for the 
Diagnosis and Management of Asthma recommends rescue medications to treat acute 
symptoms and exacerbations, and long-term controller medications to achieve and maintain 
control of persistent asthma [2]. A stepwise approach to therapy, in which the number and 
frequency of medications are increased as asthma worsens and decreased as control is 
achieved, is recommended to maintain optimum control of asthma symptoms with the lowest 
possible dose of medications [2].
Early diagnosis and removal of asthma patients from workplace exposures have been shown 
to improve WRA symptoms [4, 6-8]. However, some adults elect to remain in their current 
workplace because they are unable to find alternative employment. In addition, others may 
have persistent symptoms despite removal [6]. A previous study estimated that 62% of the 
WRA patients have poorly controlled asthma [3]. Underutilization of available asthma 
treatments and poor management may be reflected in more frequent emergency department 
visits and hospitalizations, particularly as seen among adults with WRA [5, 9].
Previous studies using data from the Behavioral Risk Factor Surveillance System (BRFSS) 
Asthma Call-back Survey have assessed controller medications among adults with current 
asthma [10, 11]. Knoeller et al. [9] found that adults with WRA take significantly more 
prescription medications than those with non-WRA. However, a detailed analysis of 
medications taken by adults with WRA has not been performed [9-11]. Also, asthma 
severity in these studies has not been assessed using the 2009 European Respiratory Society 
(ERS) and the American Thoracic Society (ATS) guidelines that defined severity as the 
difficulty in controlling asthma with treatment [3, 12, 13]. Here, we report on asthma 
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medications and asthma severity among adults with WRA using data from the 2012–2013 
Asthma Call-back Survey.
Methods
The BRFSS is a state-based, random-digit-dialed landline and cellular telephone survey of 
the non-institutionalized U.S. population aged ≥18 years that collects information on health 
risk factors, preventive health practices, and disease status [14]. BRFSS includes a standard 
set of core questions, optional modules, and state-added questions. BRFSS respondents who 
have ever been told by a health professional that they have asthma are invited to participate 
in the Asthma Call-back Survey, an optional module [15]. Those who agree to participate are 
interviewed within 2 weeks of the initial BRFSS interview and detailed information on 
asthma, including WRA, is collected. The Asthma Call-back Survey was administered 
among adults in 22 states in 2012 and 28 states in 2013. The median American Association 
for Public Opinion Research response rate in 2012 among the 22 states was 44.9% (range: 
27.7–56.8%) for BRFSS and 47.2% (range: 38.5–60.6%) for Asthma Call-back Survey, and 
in 2013 among the 28 states was 43.9% (range: 31.1–57.2%) for BRFSS and 46.0% (range: 
32.5–57.1%) for Asthma Call-back Survey. The Institutional Review Board at the Centers 
for Disease Control and Prevention has granted a surveillance exemption for BRFSS. 
Participating states are subject to state-specific Institutional Review Board requirements. 
Reports of selected statistical indicators of 2013 BRFSS data quality (outcome measures, 
selection biases, and missing values) are available at http://www.cdc.gov/brfss/annual_data/
2013/pdf/2013_dqr.pdf.
Using previously established definitions, this study analyzed data on the ever-employed 
adults with current asthma [3, 9, 12]. Survey participants who responded “yes” to the 
questions “Have you ever been told by a doctor or other health professional that you have 
asthma?” and “Do you still have asthma?” had current asthma. Ever-employed participants 
were those who indicated that they were currently employed full-time, part-time, or had ever 
been employed. Participants who responded “yes” to the question “Have you ever been told 
by a doctor or other health professional that your asthma was caused by, or your symptoms 
made worse by, any job you ever had?” had WRA. Adults with possible WRA were those 
who did not have WRA and described their asthma as caused by or made worse by things 
like chemicals, smoke, dust, or mold in their current or previous job. Adults with current 
asthma who did not have WRA or possible WRA had non-WRA.
The Asthma Call-back Survey asked respondents about their prescription medication use 
during the 3 months preceding the interview. For this study, medications were classified as 
controller (i.e., long-acting β-agonist [LABA], inhaled corticosteroid, oral corticosteroid, 
cromolyn/nedocromil, leukotriene pathway inhibitor, methylxanthine, anti-cholinergics) or 
rescue (i.e., short-acting β-agonist [SABA]) and grouped into six treatment groups following 
EPR-3 guidelines (online Appendix 1) [2].
Smoking status was defined as current (i.e., smoked ≥100 cigarettes during lifetime and 
currently smoke every day or some days), former (i.e., smoked ≥100 cigarettes during 
lifetime and currently do not smoke at all), and never (i.e., never smoked or smoked <100 
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cigarettes during lifetime). Adverse asthma outcomes, including asthma attack, emergency 
room visit, hospital stay, and urgent treatment for worsening asthma in the last 12 months, 
were classified using previously developed definitions [3, 9]. Asthma control was defined 
according to EPR-3 guidelines and categorized into well controlled, not well controlled, and 
very poorly controlled based on the category with the most severe impairment using 
responses to questions on asthma symptoms, nighttime awakenings, and SABA medication 
use for symptom control [2, 3].
Asthma severity was defined, using EPR-3 and the ERS/ATS Severe Asthma Guidelines, as 
intermittent and persistent according to respondents’ level of asthma control and use of 
asthma controller medications [2, 16]. Adults with well-controlled asthma not using long-
term control medications had intermittent asthma. Adults using long-term control 
medications, regardless of their asthma control, and those with uncontrolled asthma not 
taking long-term control medications had persistent asthma.
The 2012–2013 Asthma Call-back Survey data collected from 29 states using landline and 
cellular telephone samples were weighted to account for non-coverage, unequal probability 
of sample selection, and survey non-response to produce estimates which are representative 
of these state populations. Analyses were performed using SAS software version 9.3 (SAS 
Institute Inc., Cary, NC) and SUDAAN release 11.0.1 software (Research Triangle Institute, 
Research Triangle Park, NC). Data from 2012 to 2013 were combined and re-weighted by 
multiplying the percentage of subjects in each state and survey year by the corresponding 
survey year’s weight. Weights were unaltered for states with 1 year of data available. 
Estimates were not reported if the relative standard error was >30% or the estimate was 
based on a sample of <50 respondents [14].
We examined demographic and clinical characteristics of ever-employed adults with current 
asthma. The Rao–Scott chi-square test was used to assess associations between selected 
characteristics and a history of using asthma medications. A multivariate logistic regression 
was used to calculate adjusted prevalence ratios (PRs) for the associations among WRA 
status, asthma medications (drug class and treatment group), adverse asthma outcomes, and 
asthma control by asthma medication use. Age (continuous), sex, race/ethnicity, income, 
education, current employment status, smoking status, health insurance, chronic obstructive 
pulmonary disease (COPD), depression, and adverse asthma outcomes were all 
independently associated with WRA status and a history of taking asthma medication, and 
were simultaneously included in the multivariate logistic regression models. Using backward 
selection, non-significant covariates were removed from the model. Sex and race/ethnicity 
remained in the model regardless of significance because previous research has shown 
associations with either WRA status or asthma medication [17, 18]. Results were considered 
statistically significant at an alpha of <0.05.
Results
In the 29 states during 2012–2013, a sample of 20 823 adults participated in the Asthma 
Call-back Survey. Of these, 14 915 were ever-employed adults with current asthma. 
Participants with no current asthma (n = 5,123), who were never employed (n = 305), and 
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with missing information on employment or current asthma status (n = 480) were excluded 
from analyses.
Among an estimated 15 million ever-employed adults with current asthma in these 29 states, 
an estimated 14.7% had WRA and an additional 40.4% had possible WRA (Table 1). 
Overall, 64.9% (95% CI = 63.0–66.8) of the ever-employed adults with current asthma used 
any asthma medication in the 3 months preceding the interview; this proportion varied from 
69.5% for adults with WRA to 67.3% for adults with possible WRA, and 61.2% for those 
with non-WRA. Age, sex, health insurance, and smoking status were significantly associated 
with a history of asthma medication use in the 3 months preceding the interview (Table 1).
Proportion of ever-employed adults with current asthma taking asthma controller 
medications by the number of medications and WRA status is shown in Table 2. Compared 
with adults with non-WRA, those with WRA and possible WRA were more likely to be 
taking ≥3 asthma controller medications (PR = 2.66, 95% CI = 1.67–4.26 and PR = 1.98, 
95% CI = 1.34–2.93, respectively).
Proportion of ever-employed adults with current asthma taking specific asthma medications 
by asthma drug class and WRA status is shown in Table 3. Those with WRA were more 
likely to be taking anti-cholinergics (PR = 1.80, 95% CI = 1.05–3.06), leukotriene pathway 
inhibitor (PR = 1.59, 95% CI = 1.22–2.07), and methylxanthine (PR = 4.76, 95% CI = 2.06–
11.0) than those without WRA (Table 3). Furthermore, an analysis by treatment regimen 
showed that, compared with non-WRA, adults with WRA were more likely to be taking a 
combination of inhaled corticosteroids and either a leukotriene pathway inhibitor or 
methylxanthine in addition to taking SABA as needed (PR = 2.21, 95% CI = 1.57–3.11) 
(Table 4). Those with possible WRA were more likely to be taking methylxanthine (PR = 
2.85, 95% CI = 1.55–5.23) (Table 3), and were more likely to be taking a combination of 
inhaled corticosteroids and either a leukotriene pathway inhibitor or methylxanthine in 
addition to SABA (PR = 1.41, 95% CI = 1.05–1.89) (Table 4).
Associations among WRA, adverse asthma outcomes, and asthma control by history of 
medication use are shown in Table 5. Adults with WRA were more likely than those with 
non-WRA to have adverse asthma outcomes in the last 12 months including an asthma 
attack (PR = 1.62, 95% CI = 1.47–1.79), urgent treatment for worsening asthma (PR = 1.51, 
95% CI = 1.28–1.77), an asthma-related emergency room visit (PR = 1.65, 95% CI = 1.24–
2.20), and to have very poorly controlled asthma (PR = 1.54, 95% CI = 1.28–1.86). By a 
history of asthma medication use in the last 3 months, the associations between WRA and 
having an asthma attack (PR = 2.16, 95% CI = 1.72–2.70), and unscheduled treatment (PR = 
2.13, 95% CI = 1.38–3.30) were stronger among adults who did not take asthma medication 
compared with those who took asthma medication (PR = 1.42, 95% CI = 1.28–1.57 and PR 
= 1.18, 95% CI = 1.02–1.35, respectively). Also, very poorly controlled asthma remained 
associated with WRA among individuals who had taken medications in the last 3 months 
(Table 5).
By asthma severity, 75.2% of the adults with WRA had persistent asthma, compared to 
57.9% of the adults with non-WRA (PR = 1.07, 95% CI = 0.98–1.18). Similarly, 69.8% of 
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the adults with possible WRA had persistent asthma, significantly greater than those with 
non-WRA (PR = 1.09, 95% CI = 1.02–1.16).
Discussion
This is the first study to use Asthma Call-back Survey data to evaluate the specific use of 
asthma medication among adults with WRA. Results indicate that adults with WRA were 
more likely than those with non-WRA to be taking less commonly prescribed medications, 
including anti-cholinergics, leukotriene pathway inhibitors, and methylxanthines. Those 
with possible WRA were more likely to be taking methylxanthines than those with non- 
WRA. Moreover, adults with WRA were significantly more likely than those with non-
WRA to have used two or more controller medications, and to be taking medications 
recommended for controlling severe asthma symptoms (i.e., combination of inhaled 
corticosteroid and either a leukotriene pathway inhibitor or methylxanthine in addition to 
SABA, as needed). These findings are consistent with previous reports using data from 
Asthma Call-back Survey that persons with WRA used significantly more asthma 
medications in the past 3 months than individuals with non-WRA (1.5 vs 1.3; p < 0.001) and 
those with WRA had more severe asthma symptoms, higher healthcare utilization, and less 
well-controlled asthma than those with non-WRA [3, 9, 12].
Early diagnosis and elimination of exposures may resolve asthma symptoms and should be 
considered first in the management of asthma [4, 6-8]. In addition, the reduction of exposure 
may be considered when appropriate for some adults with irritant-induced asthma and 
asthma exacerbated by work [4, 6, 7, 19]. However, WRA is often under recognized and, if it 
is diagnosed, may be difficult to manage, resulting in delayed or inadequate medical care [4, 
20]. A recent study showed as few as one in seven employed adults with asthma talk to their 
clinician about the possible relation between work and their asthma [21]. Moreover, some 
adults may choose to remain in their current workplace, and thus exposed, due to adverse 
social and financial consequences associated with job loss or job change [22]. The large 
proportion of adults taking medications in this study may represent a missed opportunity for 
control of exposures or removal, and the subsequent need for pharmaceutical intervention. 
Physicians should collect a thorough occupational history in all working adults with new-
onset or exacerbated asthma. Establishing a WRA diagnosis and recommending appropriate 
management are necessary to improve health outcomes among these individuals [4, 6, 8].
In this study, adults with WRA were more likely than adults with non-WRA to be taking 
anti-cholinergic medications (i.e., ipratropium bromide, a bronchodilator indicated for the 
treatment of COPD) [23]. While ipratropium bromide has been used in addition to SABA to 
treat asthma attacks, its use among adults with WRA may suggest asthma–COPD overlap 
syndrome (ACOS) [24]. ACOS is characterized by overlapping clinical features of both 
asthma and COPD, and has been associated with more symptoms and worse outcomes than 
asthma or COPD alone [25-28]. Results from a previous report using the 2006–2008 Asthma 
Call-back Survey data indicated that 52% of the adults with WRA also have COPD [3]. An 
ACOS diagnosis among adults with WRA not responding to traditional asthma medication 
despite adherence to treatment guidelines may lead to better clinical characterization and 
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improved treatment among these patients [25]. Future studies should examine how overlap 
between COPD and WRA may impact WRA management.
Optimal control of asthma depends on the avoidance or reduction of exposures, correct 
inhaler technique, medication compliance, and appropriate recognition and response to an 
asthma episode [2, 4, 29, 30]. Lack of asthma control among adults with WRA may be 
explained, in part, by inadequate asthma management education in some patients (e.g., older 
adults, those with less formal education, and cigarette smokers) [31]. Moreover, asthma-
related misconceptions (i.e., patients only have asthma when symptoms are present, asthma 
can be cured rather than symptoms controlled) and low health literacy may contribute to 
poor asthma medication compliance and adverse health outcomes [32].
Over one-third of the adults were not taking any asthma medications in the last 3 months, 
despite evidence of adverse asthma outcomes and uncontrolled asthma symptoms among 
some of these individuals. Moreover, over half of the adults with WRA and possible WRA 
were not taking any controller medications. This was similar to the findings by Zahran et al. 
[10] who found that only 53% of the adults with uncontrolled asthma were on long-term 
control medications. Adults may perceive taking asthma medication to have greater risks 
than benefits, or their asthma to be well controlled when it is not, and may not take asthma 
medications as prescribed [32-34]. Additionally, over a quarter of the adults with WRA 
experience financial barriers and may take less than the recommended dose or are unable to 
buy medications [9]. However, because the Asthma Call-back Survey is a cross-sectional 
survey, the temporal relationship of adverse asthma outcomes to a history of asthma 
medication use could not be established.
At least four asthma phenotypes (i.e., paucigranulocytic, eosinophil predominant, neutrophil 
predominant, and mixed granulocytic) have been identified through a cluster of analyses of 
clinical, physiological, and laboratory features [5, 35]. Available treatments may be less 
effective for some asthma phenotypes with more severe symptoms; thus, distinguishing 
asthma phenotypes among workers with WRA may provide the opportunity for more 
targeted treatment options for some patients with WRA [2, 5, 36]. Biological treatments 
have been developed to treat severe allergic asthma and include omalizumab, mepolizumab, 
and reslizumab [37-40]. In this study, only one respondent indicated using omalizumab in 
the 3 months preceding the interview. The American College of Chest Physicians concluded 
that immunotherapy may effectively manage sensitizer-induced occupational asthma when 
the causative agent cannot be avoided and the allergen extract is available [4, 6]. However, 
limited evidence exists on the efficacy of immunotherapy for adults with WRA. Exposure 
avoidance is the preferred primary strategy to reduce signs and symptoms of WRA. Removal 
of the workers with sensitizer-induced WRA from further exposure in addition to another 
asthma management may be necessary [4, 41].
This study is subject to additional limitations. Information on asthma and medications was 
self-reported and not validated by medical records or follow up with health care providers. 
Also, the survey did not collect information on the medication dose or duration of treatment; 
thus, it was necessary to combine some treatment groups (i.e., low-dose inhaled 
corticosteroid, medium-dose inhaled corticosteroid, and high-dose inhaled corticosteroid). 
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The Asthma Call-back Survey was not designed to collect information on the timing of 
WRA diagnosis or episodes of asthma worsening. Moreover, no data were available to 
categorize WRA cases as new-onset or work-exacerbated asthma. Small sample sizes for 
some subgroups resulted in unreliable estimates that were not reported. Finally, data used in 
this analysis were for adults living in 29 states; therefore, results may not be nationally 
representative or representative of non-participating states.
Conclusions
The results of this study provide additional evidence of severe asthma among individuals 
with WRA. Adults with WRA were taking more medications for their asthma and those less 
commonly prescribed medications typically recommended for more severe asthma 
symptoms; however, despite treatment, adults with WRA were still more likely to have 
adverse asthma outcomes and less well-controlled asthma than adults with non-WRA. 
Collection of detailed information on occupational exposures, asthma triggers, and 
determination of asthma phenotype is critical for accurate WRA diagnosis and 
implementation of targeted interventions to achieve optimal asthma symptom control [4, 20]. 
Physicians should focus on optimizing and intensifying guideline-directed treatment to 
improve asthma control, and may consider prescribing phenotype-specific treatments [2]. 
Physicians should also consider counseling patients to reduce or avoid workplace exposures, 
particularly for patients with difficult-to-control or sensitizer-induced asthma [4].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors thank the Behavioral Risk Factor Surveillance System state coordinators for their assistance in 
collecting the data used in this analysis. The authors also thank Dr. Susan Tarlo, University of Toronto, Toronto 
Western Hospital, and Dr. Carrie Redlich, Yale University School of Medicine, for their helpful comments, and Dr. 
Hatice Zahran, National Center for Environmental Health, Centers for Disease Control and Prevention, for her 
advice on coding the Asthma Call-back Survey medications section data.
References
1. Moorman JE, Akinbami LJ, Bailey CM, Zahran HS, King ME, Johnson CA, et al. National 
surveillance of asthma: United States, 2001–2010. Vital Health Stat. 2012; 3(35):1–67.
2. Expert Panel Report 3 (EPR-3). Guidelines for the Diagnosis and Management of Asthma-Summary 
Report 2007. J Allergy Clin Immunol. 2007; 120(5 Suppl):S94–138. [PubMed: 17983880] 
3. Knoeller GE, Mazurek JM, Moorman JE. Characteristics associated with health care professional 
diagnosis of work-related asthma among individuals who describe their asthma as being caused or 
made worse by workplace exposures. J Occup Environ Med. 2012; 54(4):485–490. [PubMed: 
22453813] 
4. Tarlo SM, Balmes J, Balkissoon R, Beach J, Beckett W, Bernstein D, et al. Diagnosis and 
management of work-related asthma: American College of Chest Physicians Consensus Statement. 
Chest. 2008; 134(3 Suppl):1S–41S. [PubMed: 18779187] 
5. GalanterJ, , BousheyH. Chapter 20: Drugs Used in Asthma. In: KatzungB, , TrevorA, editorsBasic 
& clinical pharmacology13th ed. New York, NY: McGraw-Hill; 2015339357
6. Vandenplas O, Dressel H, Nowak D, Jamart J. What is the optimal management option for 
occupational asthma? Eur Respir Rev. 2012; 21(124):97–104. [PubMed: 22654081] 
Dodd and Mazurek Page 8
J Asthma. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
7. Tarlo S. Clinical aspects of work-related asthma: past achievements, persistent challenges, and 
emerging triggers. J Occup Environ Med. 2014; 56(Suppl 10):S40–44.
8. Baur X, Sigsgaard T, Aasen TB, Burge PS, Heederik D, Henneberger P, et al. Guidelines for the 
management of work-related asthma. Eur Respir J. 2012; 39(3):529–545. [PubMed: 22379148] 
9. Knoeller GE, Mazurek JM, Moorman JE. Work-related asthma, financial barriers to asthma care, 
and adverse asthma outcomes: Asthma Call-Back survey, 37 states and District of Columbia, 2006 
to 2008. Med Care. 2011; 49(12):1097–1104. [PubMed: 22002642] 
10. Zahran HS, Bailey CM, Qin X, Moorman JE. Assessing asthma control and associated risk factors 
among persons with current asthma - findings from the child and adult Asthma Call-back Survey. J 
Asthma. 2015; 52(3):318–326. [PubMed: 25144551] 
11. Zahran HS, Bailey CM, Qin X, Johnson C. Long-term control medication use and asthma control 
status among children and adults with asthma. J Asthma. 2017 Epub. 
12. Knoeller GE, Mazurek JM, Moorman JE. Asthma symptoms among adults with work-related 
asthma. J Asthma. 2013; 50(2):166–173. [PubMed: 23259750] 
13. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official 
American Thoracic Society/European Respiratory Society statement: asthma control and 
exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir 
Crit Care Med. 2009; 180(1):59–99. [PubMed: 19535666] 
14. Centers for Disease Control and Prevention (CDC). [April 27, 2015] Behavioral Risk Factor 
Surveillance System. Updated March 19; Available from: http://www.cdc.gov/brfss/about/
index.htm
15. Centers for Disease Control and Prevetion (CDC). BRFSS Asthma Call-back SurveyAccessed 
April 27, 2015. Updated June 9; Available from: http://www.cdc.gov/brfss/acbs/index.htm
16. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS 
guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43(2):343–
373. [PubMed: 24337046] 
17. Knoeller GE, Mazurek JM, Moorman JE. Work-related asthma among adults with current asthma 
in 33 states and DC: evidence from the Asthma Call-back Survey, 2006– 2007. Public Health Rep. 
2011; 126(4):603–611. [PubMed: 21800756] 
18. Deshpande M, Chewning B, Mott D, Thorpe JM, Young HN. Asthma medication use among late 
midlife US Adults. J Asthma. 2016; 53(3):261–268. [PubMed: 26365527] 
19. Henneberger PK, Redlich CA, Callahan DB, Harber P, Lemiere C, Martin J, et al. An official 
American Thoracic Society statement: work-exacerbated asthma. Am J Respir Crit Care Med. 
2011; 184(3):368–378. [PubMed: 21804122] 
20. Legiest B, Nemery B. Management of work-related asthma: guidelines and challenges. Eur Respir 
Rev. 2012; 21(124):79–81. [PubMed: 22654078] 
21. Mazurek JM, Storey E. Physician-patient communication regarding asthma and work. Am J Prev 
Med. 2012; 43(1):72–75. [PubMed: 22704750] 
22. Vandenplas O, Toren K, Blanc PD. Health and socioeconomic impact of work-related asthma. Eur 
Respir J. 2003; 22(4):689–697. [PubMed: 14582924] 
23. Alvarado-Gonzalez A, Arce I. Tiotropium Bromide in chronic obstructive pulmonary disease and 
bronchial asthma. J Clin Med Res. 2015; 7(11):831–839. [PubMed: 26491494] 
24. Global Initiative for Asthma GIfCOLD. Diagnosis of Diseases of Chronic Airflow Limitation: 
Asthma COPD and Asthma-COPD Overlap Syndrome (ACOS). 2015
25. van den Berge M, Aalbers R. The asthma-COPD overlap syndrome: how is it defined and what are 
its clinical implications? J Asthma Allergy. 2016; 9:27–35. [PubMed: 26929652] 
26. Nielsen M, Barnes CB, Ulrik CS. Clinical characteristics of the asthma-COPD overlap syndrome–a 
systematic review. Int J Chron Obstruct Pulmon Dis. 2015; 10:1443–1454. [PubMed: 26251584] 
27. Alshabanat A, Zafari Z, Albanyan O, Dairi M, FitzGerald JM. Asthma and COPD overlap 
syndrome (ACOS): A systematic review and meta analysis. PLoS One. 2015; 10(9):e0136065. 
[PubMed: 26336076] 
28. Malo JL, Tarlo SM, Sastre J, Martin J, Jeebhay MF, Le Moual N, et al. An official American 
Thoracic Society Workshop Report: presentations and discussion of the fifth Jack Pepys Workshop 
Dodd and Mazurek Page 9
J Asthma. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
on Asthma in the Workplace. Comparisons between asthma in the workplace and non-work-related 
asthma. Ann Am Thoracic Soc. 2015; 12(7):S99–s110.
29. Scichilone N. Asthma control: the right inhaler for the right patient. Adv Ther. 2015; 32(4):285–
292. [PubMed: 25845769] 
30. Price D, Harrow B, Small M, Pike J, Higgins V. Establishing the relationship of inhaler 
satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional 
survey of US adult asthma patients and physicians. World Allergy Org J. 2015; 8(1):26.
31. Zahran HS, Person CJ, Bailey C, Moorman JE. Predictors of asthma self-management education 
among children and adults–2006–2007 Behavioral Risk Factor Surveillance System Asthma Call-
back Survey. J Asthma. 2012; 49(1):98–106. [PubMed: 22216949] 
32. Federman AD, Wolf M, Sofianou A, Wilson EA, Martynenko M, Halm EA, Leventhal H, et al. The 
association of health literacy with illness and medication beliefs among older adults with asthma. 
Patient Educ Couns. 2013; 92(2):273–278. [PubMed: 23523196] 
33. Ponieman D, Wisnivesky JP, Leventhal H, Musumeci-Szabo TJ, Halm EA. Impact of positive and 
negative beliefs about inhaled corticosteroids on adherence in innercity asthmatic patients. Ann 
Allergy Asthma Immunol. 2009; 103(1):38–42. [PubMed: 19663125] 
34. Barnes PJ. Achieving asthma control. Curr Med Res Opin. 2005; 21(Suppl 4):S5–9.
35. Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, Wenzel SE, et al. Sputum neutrophil 
counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin 
Immunol. 2014; 133(6):1557–1563. [PubMed: 24332216] 
36. de Nijs SB, Venekamp LN, Bel EH. Adult-onset asthma: is it really different? Eur Respir Rev. 
2013; 22(127):44–52. [PubMed: 23457164] 
37. U.S. Food and Drug Administration. Omalizumab Product Approval Information - Licensing 
ActionAccessed August 1, 2016. Updated May 6, 2016; Available from: http://www.fda.gov/
drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/
therapeuticbiologicapplications/ucm093373.htm
38. Omalizumab [package insert]Genentech, Inc.; South San Francisco, CA: Accessed August 1, 2016. 
Available from: http://www.fda.gov/downloads/drugs/developmentapprovalprocess/
howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/
ucm113454.pdf
39. U.S. Food and Drug Administration. Cinqair (reslizumab)Accessed 22 August, 2016. Updated 5 
May 2016. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/
2016/761033Orig1s000TOC.cfm
40. U.S. Food and Drug Administration. Nucala (mepolizumab) Lyophilized Powder for Subcutaneous 
InjectionAccessed 22 August, 2016. Updated 11 December 2015. Available from: http://
www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125526Orig1s000TOC.cfm
41. Heederik D, Henneberger PK, Redlich CA. Primary prevention: exposure reduction, skin exposure 
and respiratory protection. Eur Respir Rev. 2012; 21(124):112–124. [PubMed: 22654083] 
Dodd and Mazurek Page 10
J Asthma. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dodd and Mazurek Page 11
Ta
bl
e 
1
Ch
ar
ac
te
ris
tic
s o
f e
v
er
-
em
pl
oy
ed
 a
du
lts
 w
ith
 c
ur
re
nt
 a
sth
m
a 
by
 h
ist
or
y 
of
 m
ed
ic
at
io
n 
us
e 
in
 th
e 
la
st 
3 
m
on
th
s.
N
o.
 in
 S
am
pl
ea
W
ei
gh
te
d
M
ed
ic
at
io
n 
us
e 
in
 la
st
 3
 m
on
th
s
%
b  
(95
%
 C
I)
N
o 
m
ed
ic
at
io
n 
us
e 
in
 la
st
 3
 m
on
th
s
%
b  
(95
%
 C
I)
N
o.
a
%
b  
(95
%
 C
I)
To
ta
l
14
 9
15
15
 1
20
 7
62
10
0.
0
10
0.
0
A
ge
c
 
18
–4
4
30
99
6 
84
1 
49
8
45
.4
 (4
3.4
–4
7.4
)
40
.4
 (3
7.9
–4
2.8
)
54
.7
 (5
1.4
–5
8.1
)
 
45
–6
4
68
24
5 
59
1 
02
0
37
.1
 (3
5.4
–3
8.8
)
39
.5
 (3
7.3
–4
1.6
)
32
.8
 (2
9.8
–3
5.7
)
 
≥6
5
49
29
2 
63
4 
58
1
17
.5
 (1
6.4
–1
8.6
)
20
.2
 (1
8.7
–2
1.6
)
12
.5
 (1
1.0
–1
4.0
)
Se
x
c
 
M
al
e
43
07
5 
20
6 
98
1
34
.4
. (3
2.6
–3
6.3
)
32
.7
 (3
0.5
–3
4.8
)
37
.7
 (3
4.3
–4
1.2
)
 
Fe
m
al
e
10
 6
08
9 
91
3 
78
0
65
.6
 (6
3.7
–6
7.4
)
67
.3
 (6
5.2
–6
9.5
)
62
.3
 (5
8.8
–6
5.7
)
R
ac
e/
et
hn
ic
ity
 
N
on
-H
isp
an
ic
, w
hi
te
11
 7
94
10
 5
17
 6
31
70
.5
 (6
8.6
–7
2.5
)
71
.0
 (6
8.5
–7
3.4
)
69
.8
 (6
6.3
–7
3.3
)
 
N
on
-H
isp
an
ic
, b
la
ck
11
24
1 
84
0 
60
1
12
.3
 (1
0.9
–1
3.8
)
12
.8
 (1
1.0
–1
4.5
)
11
.6
 (9
.2–
14
.0)
 
H
isp
an
ic
69
5
1 
54
7 
54
8
10
.4
 (8
.9–
11
.9)
9.
1 
(7.
3–
10
.9)
12
.7
 (9
.9–
15
.6)
 
O
th
er
11
08
1 
00
5 
12
1
6.
7 
(5.
6–
7.9
)
7.
2 
(5.
6–
8.7
)
5.
9 
(4.
2–
7.7
)
Ed
uc
at
io
n
 
≤H
ig
h 
sc
ho
ol
53
56
5 
55
8 
67
6
36
.8
 (3
4.9
–3
8.7
)
37
.2
 (3
5.0
–3
9.5
)
36
.0
 (3
2.7
–3
9.3
)
 
So
m
e 
co
lle
ge
45
40
5 
60
7 
02
5
37
.1
 (3
5.2
–3
9.1
)
36
.4
 (3
4.1
–3
8.7
)
38
.5
 (3
4.9
–4
2.0
)
 
Co
lle
ge
 g
ra
du
at
e
50
03
3 
94
2 
69
4
26
. 1
 (2
4.6
–2
7.6
)
26
.4
 (2
4.6
–2
8.2
)
25
.6
 (2
2.8
–2
8.4
)
H
ou
se
ho
ld
 in
co
m
e
 
<
$1
5,0
00
25
86
2 
29
9 
21
1
17
.1
 (1
5.6
–1
8.6
)
18
.0
 (1
6.2
–1
9.8
)
15
.4
 (1
2.7
–1
8.1
)
 
$1
5,0
00
–$
24
,99
9
27
79
2 
47
0 
87
7
18
.4
 (1
6.9
–1
9.9
)
17
.7
 (1
5.9
–1
9.5
)
19
.6
 (1
7.0
–2
2.2
)
 
$2
5,0
00
–$
34
,99
9
14
82
1 
36
3 
07
1
10
.1
 (8
.9–
11
.4)
10
.3
 (8
.9–
11
.6)
9.
9 
(7.
5–
12
.3)
 
$3
5,0
00
–$
49
,99
9
17
57
1 
65
4 
11
5
12
.3
 (1
1.1
–1
3.5
)
12
.3
 (1
0.8
–1
3.7
)
12
.3
 (1
0.1
–1
4.5
)
 
≥$
50
,00
0
48
34
5 
66
4 
15
1
42
.1
 (4
0.1
–4
4.1
)
41
.7
 (3
9.4
–4
4.1
)
42
.8
 (3
9.2
–4
6.4
)
H
ea
lth
 in
su
ra
nc
ec
 
Ye
s
13
 4
93
13
 0
69
 4
39
86
.6
 (8
5.2
–8
8.0
)
88
.3
 (8
6.6
–9
0.0
)
83
.6
 (8
1.1
–8
6.1
)
 
N
o
13
90
2 
01
6 
30
8
13
.4
 (1
2.0
–1
4.8
)
11
.7
 (1
0.0
–1
3.4
)
16
.4
 (1
3.9
–1
8.9
)
Sm
ok
in
g 
sta
tu
sc
J Asthma. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dodd and Mazurek Page 12
N
o.
 in
 S
am
pl
ea
W
ei
gh
te
d
M
ed
ic
at
io
n 
us
e 
in
 la
st
 3
 m
on
th
s
%
b  
(95
%
 C
I)
N
o 
m
ed
ic
at
io
n 
us
e 
in
 la
st
 3
 m
on
th
s
%
b  
(95
%
 C
I)
N
o.
a
%
b  
(95
%
 C
I)
 
Cu
rre
nt
25
68
3 
01
7 
33
2
20
.0
 (1
8.4
–2
1.6
)
20
.7
 (1
8.8
–2
2.6
)
18
.7
 (1
5.8
–2
1.6
)
 
Fo
rm
er
50
68
4 
15
2 
73
3
27
.5
 (2
5.9
–2
9.1
)
30
.4
 (2
8.4
–3
2.4
)
22
.2
 (1
9.6
–2
4.8
)
 
N
ev
er
72
37
7 
91
0 
92
1
52
.5
 (5
0.5
–5
4.4
)
48
.9
 (4
6.6
–5
1.2
)
59
.1
 (5
5.7
–6
2.5
)
A
sth
m
a 
sta
tu
s
 
W
RA
23
38
2 
22
4 
26
3
14
.7
 (1
3.4
–1
6.0
)
15
.8
 (1
4.1
–1
7.4
)
12
.8
 (1
0.6
–1
5.0
)
 
Po
ss
ib
le
 W
RA
62
09
6 
09
4 
06
4
40
.4
 (3
8.5
–4
2.2
)
41
.8
 (3
9.6
–4
4.1
)
37
.6
 (3
4.2
–4
0.9
)
 
N
on
-W
RA
63
38
6 
78
4 
07
2
44
.9
 (4
3.0
–4
6.9
)
42
.4
 (4
0.1
–4
4.7
)
49
.6
 (4
6.1
–5
3.1
)
A
sth
m
a 
co
nt
ro
l
 
W
el
l c
on
tro
lle
d
67
43
7 
55
4 
00
8
50
.0
 (4
8.0
–5
1.9
)
47
.4
 (3
6.1
–5
8.6
)
96
.3
 (9
5.0
–9
7.5
)
 
N
ot
 w
el
l c
on
tro
lle
d
39
59
3 
85
5 
75
1
25
.5
 (2
3.9
–2
7.1
)
21
.0
 (1
1.6
–3
0.4
)
3.
0 
(1.
8–
4.1
)
 
Ve
ry
 p
oo
rly
 c
on
tro
lle
d
42
10
3 
71
0 
70
4
24
.5
 (2
3.0
–2
6.1
)
31
.6
 (2
0.8
–4
2.4
)
—
A
dv
er
se
 a
st
hm
a 
ou
tc
om
es
 
A
sth
m
a 
at
ta
ck
 in
 p
as
t 1
2 
m
on
th
sc
77
05
7 
80
7 
69
6
51
.9
 (5
0.0
–5
3.9
)
60
.6
 (5
8.3
–6
2.8
)
35
.9
 (3
2.7
–3
9.1
)
 
U
rg
en
t t
re
at
m
en
t f
or
 w
o
rs
en
in
g 
as
th
m
ac
35
28
3 
46
6 
27
5
43
.5
 (4
0.9
–4
6.1
)
64
.0
 (6
0.6
–6
7.4
)
17
.4
 (1
4.3
–2
0.5
)
 
A
sth
m
a-
re
la
te
d 
em
er
ge
nc
y 
ro
om
 v
isi
tc
18
45
2 
04
1 
79
2
13
.5
 (1
2.2
–1
4.9
)
17
.7
 (1
5.8
–1
9.6
)
5.
8 
(4.
3–
7.3
)
 
O
ve
rn
ig
ht
 st
ay
 in
 h
os
pi
ta
l b
ec
au
se
 o
f a
sth
m
ac
55
5
54
9 
43
8
3.
6 
(2.
9–
4.4
)
4.
8 
(3.
8–
5.8
)
1.
5 
(0.
7–
2.4
)
a C
at
eg
or
ie
s d
o 
no
t s
um
 to
 to
ta
l d
ue
 to
 it
em
 n
on
-re
sp
on
se
.
b R
es
ul
ts 
pr
es
en
te
d 
as
 w
ei
gh
te
d 
an
nu
al
 av
er
ag
e.
c R
ao
–S
co
tt 
ch
i-s
qu
ar
e 
te
st 
p 
<
 0
.0
5.
J Asthma. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dodd and Mazurek Page 13
Ta
bl
e 
2
N
um
be
r o
f c
on
tro
lle
r m
ed
ic
at
io
ns
a  
ta
ke
n
 b
y 
ev
er
-
em
pl
oy
ed
 a
du
lts
 w
ith
 c
ur
re
nt
 a
sth
m
a 
by
 W
RA
 st
at
us
.
W
R
A
 (N
 =2
 22
4 2
63
)b
%
b  
(95
%
 C
I)
Po
ss
ib
le
 W
R
A
 (N
 = 
6 0
94
 06
4)b
%
b  
(95
%
 C
I)
N
on
-W
R
A
 (N
 = 
6 7
84
 07
2)b
%
b  
(95
%
 C
I)
W
R
A
 v
s N
on
-W
R
A
PR
c  
(95
%
 C
I)
Po
ss
ib
le
 W
R
A
 v
s N
on
-W
R
A
PR
c  
(95
%
 C
I)
0
50
.5
 (4
5.7
–5
5.2
)
55
.2
 (5
2.3
–5
8.1
)
60
.0
 (5
7.1
–6
2.8
)
0.
97
 (0
.88
–1
.07
)
0.
96
 (0
.89
–1
.03
)
1
27
.9
 (2
4.1
–3
1.7
)
31
.5
 (2
8.7
–3
4.4
)
30
.3
 (2
7.7
–3
3.0
)
0.
80
 (0
.67
–0
.95
)
0.
98
 (0
.86
–1
.11
)
2
16
.7
 (1
2.5
–2
0.8
)
10
.8
 (9
.3–
12
.2)
8.
4 
(7.
0–
9.7
)
1.
63
 (1
.18
–2
.24
)
1.
18
 (0
.95
–1
.47
)
≥3
5.
0 
(3.
5–
6.4
)
2.
5 
(1.
9–
3.1
)
1.
3 
(1.
0–
1.6
)
2.
66
 (1
.67
–4
.26
)
1.
98
 (1
.34
–2
.93
)
a I
n 
3 
m
on
th
s p
re
ce
di
ng
 th
e 
su
rv
ey
 in
te
rv
ie
w
.
b R
es
ul
ts 
pr
es
en
te
d 
as
 w
ei
gh
te
d 
an
nu
al
 av
er
ag
e.
c C
on
sis
ts 
of
 m
od
el
 w
he
re
 th
e 
ou
tc
om
e 
va
ria
bl
e 
w
as
 th
e 
nu
m
be
r o
f c
on
tro
lle
r m
ed
ic
at
io
ns
 ta
ke
n
 a
n
d 
th
e 
pr
ed
ic
to
r v
ar
ia
bl
e 
w
as
 W
RA
 st
at
us
, a
dju
ste
d f
or 
ag
e, 
sex
, 
ra
ce
/e
th
ni
ci
ty
,
 
in
co
m
e,
 h
ea
lth
 in
su
ra
nc
e,
 
cu
rr
en
t e
m
pl
oy
m
en
t s
ta
tu
s, 
ch
ro
ni
c 
ob
str
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e 
(C
OP
D)
, a
nd
 ad
ve
rs
e 
as
th
m
a 
ou
tc
om
es
.
W
RA
, w
o
rk
-re
la
te
d 
as
th
m
a;
 P
R,
 p
re
v
al
en
ce
 ra
tio
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; B
ol
d 
te
x
t i
nd
ic
at
es
 si
gn
ifi
ca
nc
e.
J Asthma. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dodd and Mazurek Page 14
Ta
bl
e 
3
Pr
op
or
tio
n 
of
 ev
er
-
em
pl
oy
ed
 a
du
lts
 w
ith
 c
ur
re
nt
 a
sth
m
a 
by
 a
sth
m
a 
dr
ug
 c
la
ss
 a
nd
 W
RA
 st
at
us
.
D
ru
g 
C
la
ss
 a
W
R
A
 (N
 =2
 22
4 2
63
)b
%
b  
(95
%
 C
I)
Po
ss
ib
le
 W
R
A
 (N
 =6
 09
4 0
64
)b
%
b  
(95
%
 C
I)
N
on
-W
R
A
 (N
 = 
6 7
84
 07
2)b
%
b  
95
%
 C
I
W
R
A
 v
s n
on
-W
R
A
PR
c  
(95
%
 C
I)
Po
ss
ib
le
 W
R
A
 v
s n
on
-W
R
A
PR
c  
(95
%
 C
I)
Co
nt
ro
lle
r
 
Lo
ng
-a
ct
in
g 
β-a
go
ni
st
28
.2
 (2
4.3
–3
2.1
)
23
.7
 (2
1.5
–2
6.0
)
21
.2
 (1
9.1
–2
3.3
)
1.
15
 (0
.95
–1
.39
)
1.
05
 (0
.92
–1
.21
)
 
In
ha
le
d 
co
rti
co
ste
ro
id
38
.3
 (3
3.8
–4
2.9
)
36
.0
 (3
3.2
–3
8.7
)
32
.2
 (2
9.6
–3
4.8
)
1.
04
 (0
.89
–1
.21
)
1.
06
 (0
.95
–1
.18
)
 
O
ra
l c
or
tic
os
te
ro
id
5.
5 
(3.
8–
7.3
)
3.
0 
(1.
8–
4.2
)
2.
5 
(1.
7–
3.4
)
1.
29
 (0
.83
–1
.99
)
0.
95
 (0
.62
–1
.45
)
 
Cr
om
ol
yn
/n
ed
oc
ro
m
il
—
—
—
—
—
 
Le
uk
o
tr
ie
ne
 p
at
hw
ay
 in
hi
bi
to
r
16
.0
 (1
2.7
–1
9.3
)
10
.9
 (9
.4–
12
.4)
10
.5
 (8
.7–
12
.2)
1.
59
 (1
.22
–2
.07
)
1.
22
 (0
.97
–1
.52
)
 
M
et
hy
lx
an
th
in
e
1.
8 
(0.
8–
2.8
)
1.
1 
(0.
7–
1.6
)
0.
3 
(0.
2–
0.5
)
4.
76
 (2
.06
–1
1.0
)
2.
85
 (1
.55
–5
.23
)
 
A
nt
i-c
ho
lin
er
gi
c
9.
9 
(6.
3–
13
.4)
5.
3 
(4.
3–
6.3
)
3.
5 
(2.
8–
4.2
)
1.
80
 (1
.05
–3
.06
)
1.
18
 (0
.90
–1
.56
)
R
es
cu
e
 
Sh
or
t-a
ct
in
g 
β-a
go
ni
st
61
.2
 (5
6.6
–6
5.9
)
57
.5
 (5
4.5
–6
0.4
)
50
.2
 (4
7.2
–5
3.2
)
0.
99
 (0
.88
–1
.10
)
1.
02
 (0
.95
–1
.10
)
a M
ed
ic
at
io
ns
 u
se
d 
in
 3
 m
on
th
s p
re
ce
di
ng
 th
e 
su
rv
ey
 in
te
rv
ie
w
.
b R
es
ul
ts 
pr
es
en
te
d 
as
 w
ei
gh
te
d 
an
nu
al
 av
er
ag
e.
c C
on
sis
ts 
of
 e
ig
ht
 m
od
el
s w
he
re
 th
e 
ou
tc
om
e 
va
ria
bl
es
 w
er
e 
dr
ug
 c
la
ss
 a
nd
 th
e 
pr
ed
ic
to
r v
ar
ia
bl
e 
w
as
 W
RA
 st
at
us
, a
dju
ste
d f
or 
ag
e, 
sex
, 
ra
ce
/e
th
ni
ci
ty
,
 
in
co
m
e,
 h
ea
lth
 in
su
ra
nc
e,
 c
ur
re
nt
 e
m
pl
oy
m
en
t s
ta
tu
s, 
ch
ro
ni
c 
ob
str
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e 
(C
OP
D)
, a
nd
 ad
ve
rs
e 
as
th
m
a 
ou
tc
om
es
.
CI
, c
on
fid
en
ce
 in
te
rv
al
; P
R,
 p
re
v
al
en
ce
 ra
tio
; W
RA
, w
o
rk
-re
la
te
d 
as
th
m
a;
 B
ol
d 
te
x
t i
nd
ic
at
es
 si
gn
ifi
ca
nc
e;
 “
–”
 in
di
ca
te
s r
el
at
iv
e 
st
an
da
rd
 e
rro
r >
30
%
, e
sti
m
at
e 
no
t r
ep
or
ta
bl
e.
J Asthma. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dodd and Mazurek Page 15
Ta
bl
e 
4
Pr
op
or
tio
n 
of
 ev
er
-
em
pl
oy
ed
 a
du
lts
 w
ith
 c
ur
re
nt
 a
sth
m
a 
by
 a
sth
m
a 
tre
at
m
en
t g
ro
up
a  
an
d 
W
RA
 st
at
us
.
Tr
ea
tm
en
t g
ro
u
pb
W
R
A
 (N
 =2
 22
4 2
63
)c
%
c  
(95
%
 C
I)
Po
ss
ib
le
 W
R
A
 (N
 =6
 09
4 
06
4)c
%
c  
(95
%
 C
I)
N
on
-W
R
A
 (N
 = 
6 7
84
 
07
2)c
%
c  
(95
%
 C
I)
W
R
A
 v
s n
on
-W
R
A
PR
d  
(95
%
 C
I)
Po
ss
ib
le
 W
R
A
 v
s n
on
-
W
R
A
PR
d  
(95
%
 C
I)
Sh
or
t-a
ct
in
g 
β-a
go
ni
st 
(S
AB
A
)
35
.8
 (3
0.3
–4
1.3
)
38
.3
 (3
5.0
–4
1.7
)
38
.3
 (3
4.5
–4
2.0
)
0.
90
 (0
.75
–1
.08
)
0.
91
 (0
.81
–1
.04
)
In
ha
le
d 
co
rti
co
ste
ro
id
 (I
CS
) +
 SA
BA
12
.3
 (7
.4–
17
.1)
15
.9
 (1
2.9
–1
8.8
)
16
.1
 (1
3.5
–1
8.8
)
0.
74
 (0
.47
–1
.17
)
0.
99
 (0
.77
–1
.28
)
Cr
om
ol
yn
/n
ed
oc
ro
m
il,
 le
uk
o
tr
ie
ne
 re
ce
pt
or
 a
go
ni
st 
(LT
R
A
), o
r t
he
op
hy
lli
ne
 +
 S
A
BA
8.
6 
(5.
8–
11
.3)
7.
1 
(5.
3–
8.8
)
9.
0 
(6.
7–
11
.3)
1.
11
 (0
.74
–1
.66
)
1.
03
 (0
.72
–1
.46
)
IC
S 
+ 
lo
ng
-a
ct
in
g 
β-a
go
ni
st 
(L
AB
A
) +
 SA
BA
24
.0
 (1
9.8
–2
8.1
)
26
.1
 (2
3.2
–2
9.1
)
26
.1
 (2
3.2
–2
9.0
)
0.
90
 (0
.72
–1
.12
)
1.
01
 (0
.86
–1
.18
)
IC
S 
+ 
LT
R
A
, t
he
op
hy
lli
ne
, o
r z
ile
ut
on
 +
 S
A
BA
16
.2
 (1
2.1
–2
0.2
)
10
.2
 (8
.6–
11
.8)
8.
2 
(6.
6–
9.9
)
2.
21
 (1
.57
–3
.11
)
1.
41
 (1
.05
–1
.89
)
IC
S 
+ 
LA
BA
 +
 o
ra
l c
or
tic
os
te
ro
id
 +
 S
A
BA
2.
8 
(1.
7–
3.9
)
1.
2 
(0.
7–
1.7
)
2.
0 
(1.
0–
3.1
)
1.
34
 (0
.78
–2
.30
)
0.
68
 (0
.39
–1
.19
)
a I
n 
3 
m
on
th
s p
re
ce
di
ng
 th
e 
A
sth
m
a 
Ca
ll-
ba
ck
 S
ur
ve
y 
in
te
rv
ie
w
.
b T
re
at
m
en
t g
ro
up
s b
as
ed
 o
n 
NA
EP
P 
Ex
pe
rt 
Pa
n
el
 R
ep
or
t 3
: G
ui
de
lin
es
 fo
r t
he
 D
ia
gn
os
is 
an
d 
M
an
ag
em
en
t o
f A
sth
m
a.
c R
es
ul
ts 
pr
es
en
te
d 
as
 w
ei
gh
te
d 
an
nu
al
 av
er
ag
e.
d C
on
sis
ts 
of
 m
od
el
 w
he
re
 th
e 
ou
tc
om
e 
va
ria
bl
e 
w
as
 th
e 
tre
at
m
en
t g
ro
up
 a
nd
 th
e 
pr
ed
ic
to
r v
ar
ia
bl
e 
w
as
 th
e 
W
RA
 st
at
us
, a
dju
ste
d f
or 
ag
e, 
sex
, 
ra
ce
/e
th
ni
ci
ty
,
 
in
co
m
e,
 h
ea
lth
 in
su
ra
nc
e,
 c
ur
re
nt
 e
m
pl
oy
m
en
t 
st
at
us
, c
hr
on
ic
 o
bs
tru
ct
iv
e 
pu
lm
on
ar
y 
di
se
as
e,
 a
nd
 a
dv
er
se
 a
st
hm
a 
ou
tc
om
es
.
CI
, c
on
fid
en
ce
 in
te
rv
al
; P
R,
 p
re
v
al
en
ce
 ra
tio
; W
RA
, w
o
rk
-re
la
te
d 
as
th
m
a;
 B
ol
d 
te
x
t i
nd
ic
at
es
 si
gn
ifi
ca
nc
e.
J Asthma. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dodd and Mazurek Page 16
Table 5
Adverse asthma outcomes and asthma control by history of medication use and work-related asthma (WRA) 
status.
Adverse asthma outcomes
Total
PRa (95% CI)
Medication use in last 3 months
PRa (95% CI)
No medication use in last 3 months
PRa (95% CI)
Asthma attackb
 WRA 1.62 (1.47–1.79) 1.42 (1.28–1.57) 2.16 (1.72–2.70)
 Possible WRA 1.32 (1.20–1.44) 1.24 (1.13–1.35) 1.44 (1.14–1.78)
 Non-WRA 1.00 1.00 1.00
Urgent treatmentb
 WRA 1.51 (1.28–1.77) 1.18 (1.02–1.35) 2.13 (1.38–3.30)
 Possible WRA 1.22 (1.06–1.40) 1.11 (0.98–1.24) 0.91 (0.60–1.40)
 Non-WRA 1.00 1.00 1.00
ER visitb
 WRA 1.65 (1.24–2.20) 1.40 (1.05–1.84) —
 Possible WRA 1.26 (0.99–1.61) 1.17 (0.92–1.49) 1.33 (0.73–2.42)
 Non-WRA 1.00 1.00 1.00
Overnight hospital stayb
 WRA 1.18 (0.72–1.93) 1.10 (0.65–1.84) —
 Possible WRA 1.27 (0.79–2.05) 1.33 (0.82–2.17) —
 Non-WRA 1.00 1.00 —
Well-controlled asthmac
 WRA 0.74 (0.64–0.85) 0.68 (0.54–0.85) 0.87 (0.77–0.98)
 Possible WRA 0.81 (0.75–0.88) 0.80 (0.70–0.92) 0.89 (0.81–0.96)
 Non-WRA 1.00 1.00 1.00
Not well-controlled asthmac
 WRA 1.16 (0.95–1.41) 0.99 (0.80–1.23) 1.69 (1.05–2.74)
 Possible WRA 1.19 (1.03–1.38) 1.06 (0.91–1.23) 1.65 (1.11–2.47)
 Non-WRA 1.00 1.00 1.00
Very poorly controlled asthmac
 WRA 1.54 (1.28–1.86) 1.47 (1.22–1.76) 1.49 (0.89–2.49)
 Possible WRA 1.31 (1.14–1.50) 1.22 (1.07–1.39) 1.36 (0.86–2.16)
 Non-WRA 1.00 1.00 1.00
aConsists of five models where the outcome variables were adverse asthma outcomes and asthma control and the predictor variable was WRA 
status, adjusted for age, sex, race/ethnicity, income, health insurance, current employment status, and chronic obstructive pulmonary disease among 
the total population and those reporting medication use in last 3 months.
b
In the last 12 months.
c
Based on NAEPP Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, using information on the number of days with 
any asthma symptoms and nighttime awakenings in the last 30 days, and the frequency of inhaler SABA use in the last 3 months.
CI, confidence interval; PR, prevalence ratio; WRA, work-related asthma; Bold text indicates significance; “–” indicates relative standard error 
>30%, estimate not reportable.
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